Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domain Therapeutics and Ono Sign Collaboration Agreement

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
Collaboration agreement in the field of GPCR-based drug discovery.

Domain Therapeutics S.A. has announced that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) have signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).

Under the agreement, Ono will provide Domain Therapeutics with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products.

Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform, and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono.

Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics.

Neuville continued, “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”
 
Kazuhito Kawabata, Ph.D., member of the board of directors, executive officer and executive director, discovery and research of Ono said: “We highly appreciate Domain Therapeutics’ DTect-All™ technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domain Therapeutics Appoints Professor Michel Bouvier
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs.
Tuesday, September 23, 2014
Domain Therapeutics Enters into Collaboration with XOMA
DTect-All™ platform will be used to screen for GPCR-directed allosteric modulator antibodies.
Wednesday, February 05, 2014
Domain Therapeutics Opens a North American Subsidiary at Montreal's NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All™ technology.
Tuesday, January 21, 2014
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University Sign Agreement
New licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.
Thursday, December 26, 2013
Domain Therapeutics Closes EUR Two Million Funding Round
The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs.
Wednesday, July 18, 2012
Domain Therapeutics Wins EUR 933,000 Grant for Schizophrenia Project
GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies.
Wednesday, March 14, 2012
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease.
Monday, January 17, 2011
Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!